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elimination from central compartment described gentami-
cin pharmacokinetics. Population estimates for Cl s  and Cl dial  
were 7.6 and 134 ml/min, respectively. Patient weight was 
statistically significantly associated with Cl s  and V c . Predial-
ysis every-other-day regimens were as effective (C max   6 8 
mg/l and AUC 48 h   6 140 mg  h/l) and less toxic (C min   ! 2 mg/l 
and AUC 48 h   ! 240 mg  h/l) than postdialysis regimens.  Con-
clusions: Estimated gentamicin Cl dial  is higher than previous 
estimates with thrice-weekly regimens. Predialysis every-
other-day dosing may be recommended during SDHD.
 Copyright © 2012 S. Karger AG, Basel
 Introduction
 Bacterial infections remain the second leading cause 
of death in patients with chronic kidney disease, stage 5 
(CKD-5)  [1] . Aminoglycosides remain critical for treating 
multidrug-resistant Gram-negative and Gram-positive 
infections  [2, 3] . Optimization of aminoglycoside dosing 
to ensure maximal efficacy and minimal toxicity is es-
sential. The best predictors of efficacy are the ratios of 
peak aminoglycoside plasma concentration (C max ) or 
area under the curve (AUC) to the minimum inhibitory 
concentration. Hence, dosing regimens that maximize 
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 Abstract
 Background/Aims: Gentamicin pharmacokinetics have not 
been described in patients undergoing short-daily hemodi-
alysis (SDHD). The aim of this study is to describe gentamicin 
pharmacokinetics and dialytic clearance (Cl dial ) in SDHD pa-
tients and simulate gentamicin exposure after six dosing 
regimens to help guide future dosing.  Methods: Six anuric 
patients undergoing SDHD were enrolled. Patients received 
intravenous infusion of 2 mg/kg gentamicin on day 1 after 
the first HD session followed by HD sessions on days 2, 3, and 
4. Blood samples for determination of gentamicin concen-
trations were serially collected. Gentamicin pharmacokinet-
ic parameters and Cl dial  and interindividual variability terms 
(IIV) were estimated using NONMEM VII. Influence of patient 
weight on systemic clearance (Cl s ) and central volume of dis-
tribution (V c ) and influence of urea removal estimates on 
Cl dial  were assessed. The model was used to simulate genta-
micin concentrations after six dosing regimens including 
pre- and postdialysis as well as daily and every-other-day 
dosing.  Results: A two-compartment model with first-order 
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these are expected to maximize efficacy and prevent 
emergence of resistant strains  [4] .
 Short-daily hemodialysis (SDHD), usually 2 h done 6 
days per week, is an effective alternative to conventional 
thrice-weekly 4-hour hemodialysis. SDHD improves 
quality of life and reduces medical complications (i.e. 
blood pressure reduction, hyperkalemia, inflammation) 
associated with CKD-5  [1, 5, 6] . 
 The purpose of this study was to describe gentamicin 
pharmacokinetics in patients undergoing SDHD. Fur-
thermore, the estimated gentamicin pharmacokinetic 
parameters were used to perform simulations to predict 
gentamicin exposure after six different dosing regimens. 
 Subjects and Methods
 Six noninfected anuric subjects undergoing outpatient SDHD 
at the Indiana University Outpatient Dialysis Center (Indianapo-
lis, Ind., USA) were enrolled in the study. Subjects were eligible for 
the study if they were 18 years of age or older, received regular 
SDHD six times weekly, suffered from no other acute illnesses, 
and had a postdialysis weight within 30% of ideal body weight  [7] . 
Subjects were excluded from the study if they had a history of gen-
tamicin allergy or if they received gentamicin within 3 weeks of 
enrollment. The study protocol was approved by the Indiana Uni-
versity-Purdue University-Indianapolis Institutional Review 
Board. All subjects provided written informed consent before 
participating in any study procedures. All study procedures were 
conducted in the Indiana Clinical Research Center as part of the 
Indiana Clinical and Translational Sciences Institute at Indiana 
University Hospital (Indianapolis, Ind., USA).
 Each subject received a 2-mg/kg gentamicin intravenous infu-
sion over 30 min (n = 5) or 60 min (n = 1) on day 1 after the first 
SDHD session. Blood samples were collected at the end of the di-
alysis session immediately before drug administration and then 
at 0.5, 1, 1.5, 2, 3, and 5 h after the end of dialysis/start of the gen-
tamicin infusion. On day 2, blood samples were collected just be-
fore the start, at the middle (1 h), and at the end of the second 
SDHD session and then at 0.5, 1, 2, and 4 h after the end of the 
dialysis session. On days 3 and 4, blood samples were collected 
before the start, at the middle (1 h), and at the end of the dialysis 
sessions. All samples were collected in nonheparinized evacuated 
blood collection tubes and allowed to clot. Samples were centri-
fuged and serum was harvested and stored at –70   °   C until ana-
lyzed in batch. Dialysis procedures were performed using a new 
unused cellulose triacetate high-flux dialyzer (Exeltra 150; Baxter 
Healthcare, Deerfield, Ill., USA). The dialyzer had an ultrafiltra-
tion coefficient of 31.5 ml/h per mm Hg and a surface area of 
1.5 m 2 . Serum gentamicin concentrations were determined using 
an enzyme multiplied immunoassay technique (EMIT; Syva Co., 
Dade Behring Inc., Cupertino, Calif., USA)  [8] . The lower limit of 
quantification for the assay was 0.5   g/ml with calibration curves 
constructed for concentrations up to 10   g/ml. Intraday and in-
terday coefficients of variation were less than 12% at 1   g/ml and 
8   g/ml. Urea nitrogen and creatinine concentrations were deter-
mined by colorimetric methods  [8, 9] . This assay had intra- and 
interassay coefficients of variation of  ! 5% for both urea nitrogen 
and creatinine.
 Gentamicin serum concentrations from all subjects were used 
simultaneously to perform population compartmental pharma-
cokinetic modeling using NONMEM (version VII; Globomax 
LLC, Ellicott, Md., USA). Initially, gentamicin concentrations on 
day 1 only (after the first SDHD session and before the second 
session) were used to describe gentamicin disposition without the 
effect of dialysis. A two-compartment structural pharmacokinet-
ic model  [8] was used to describe gentamicin pharmacokinetics 
during interdialysis periods (equations 1 and 2):
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 where X(1) and X(2) are the amounts of drug in the central and 
peripheral compartments, dX(1)/dt and dX(2)/dt are the rates of 
change in drug amount over time for central and peripheral com-
partments; V c  and V p  are the apparent volumes of distribution in 
the central and peripheral compartments, respectively; R 0  is the 
zero-order infusion rate; and Cl s  and Cl d  are the systemic and dis-
tribution clearances, respectively.
 The above model was used to obtain population parameter 
estimates during interdialysis periods. Subsequently, gentamicin 
concentrations from days 1–4 were used in the overall model that 
describes the additional effect of SDHD on gentamicin pharma-
cokinetics. Effect of dialysis on gentamicin elimination was mod-
eled using a third compartment representing the dialyzer. Genta-
micin dialysis clearance (Cl dial ) into the third compartment was 
turned on and off according to the schedule of dialysis sessions. 
Equation 1 was modified to express Cl dial  as shown in equation 3, 
whereas equation 5 was used to describe change in gentamicin 
amounts in the dialysis compartment, and equation 4 described 
change in gentamicin amounts in the peripheral compartment.
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 An indicator variable ‘DIAL’ with values of 1 or 0 was used to 
turn the dialysis compartment on and off, respectively, depending 
on the timing of daily dialysis sessions  [8] . Transfer of drug be-
tween the three compartments was assumed to be following first 
order processes.
 Interindividual variability (IIV) on Cl s , V c , and Cl dial  was 
modeled using an exponential IIV model assuming log-normal 
distribution of the between-subject variability in population pa-
rameter estimates. Each subject’s estimated Cl s , V c , and Cl dial  were 
therefore related to the corresponding population estimate. Re-
sidual unexplained variability, including intraindividual vari-
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ability, was modeled using an additive error term. The best struc-
tural model to describe the observed data was chosen based on 
goodness-of-fit plots and minimum value of objective function 
(OFV), as well as individual plots of observed and model-predict-
ed concentrations versus time. 
 The final structural model was used to test the effects of sub-
ject and dialysis covariates on the model parameters. The effects 
of subject weight on population parameter and IIV estimates for 
Cl s  and V c  were examined. Similarly, to determine if there was a 
significant impact of urea removal on gentamicin removal, the 
effects of single-pool Kt/V urea , equilibrated Kt/V urea , and weekly 
standard Kt/V (as dialyzer-specific covariates) on Cl dial  were eval-
uated. All urea removal estimates were calculated using standard 
methods previously described by Leypoldt et al.  [9] . Covariates 
were kept in the model if their addition resulted in a statistically 
significant decrease in OFV (a decrease of 3.84 units is considered 
statistically significant at   = 0.05 using a   2  test). The relationship 
between subject weight and each of Cl s  and V c  was described using 
a power model after correcting each subject’s weight for the me-
dian weight value according to equation 6:
 
 
2θ
1θ 91TV
WTP
? ???? ?? ??? ?                                                                          (6)
 where   1  is the typical value (population estimate) of the param-
eter (Cl s  or V c ) in a subject weighing 91 kg (median weight for the 
6 subjects), WT is the subject weight, and   2  is the power term de-
scribing the effect of subject weight on typical value of the param-
eter. A similar approach was used to test the effects of dialyzer-
specific covariates on Cl dial , but with no correction of subject val-
ues to the median of the population.
 The final model (including covariates) was used to simulate 
gentamicin plasma concentrations using NONMEM VII after six 
different dosing regimens, A 1 , A 2 , B 1 , B 2 , C 1 , and C 2 , as shown in 
 table 1 in order to determine the best dosing strategy in patients 
undergoing SDHD. All doses were simulated as 30-min infusions, 
and plasma concentrations were simulated for a 1-week interval. 
Two of those regimens (B 1  and C 1 ) had been tested in a previous 
study  [10] . Previous studies have proposed the use of AUC  6 140 
mg  h/l/48 h and C max   6 8 mg/l as pharmacodynamic targets in-
dicating achievement of concentrations high enough to cause bac-
terial killing  [8, 11] . Similarly, AUC  ^  240 mg  h/l/48 h and C min  
 ! 2 mg/l were proposed as targets indicating achievement of con-
centrations low enough between doses to avoid toxicity (i.e. non-
toxic). We used these same targets to evaluate the performance of 
six different dosing regimens. 
 Areas under the simulated plasma concentration versus time 
curves (AUC) were calculated using the linear trapezoidal meth-
od for the time intervals 0–48 (AUC 0–48 ), 48–96 (AUC 48–96 ), and 
96–144 (AUC 96–144 ) based on the simulations. Percentages of sim-
ulated subjects achieving a 48-hour interval AUC  6 140 mg  h/l/
48 h, a 48-hour interval AUC  ^  240 mg  h/l/48 h, a peak plasma 
concentration  6 8 mg/l (30 min after the end of infusion), and a 
trough (predialysis for regimen A and predose for regimens B and 
C) plasma concentration  ! 2 mg/l were calculated.
 Results
 Six subjects (1 woman and 5 men) enrolled in and 
completed the study. Subjects had a median age of 54 
years (28–59) and a median weight of 91 kg (59–110). No 
adverse effects related to gentamicin were reported. The 
dialysis blood flow rate in all subjects was 500 ml/min. 
The median (range) dialysis duration was 2.5 h (2.0–2.5). 
Observed gentamicin plasma concentration-time pro-
files were described by a two-compartment model with 
first order elimination from the central compartment. 
The effect of dialysis was described by a third compart-
ment with Cl dial  controlling the one-way transfer of drug 
from the central to the dialysis compartment during in-
tradialysis periods.  Table  2 shows the model-estimated 
population pharmacokinetic parameters with the associ-
ated IIV where applicable. Addition of IIV terms on only 
Cl s , V c , and Cl dial  led to significant improvement in the 
model evident by a significant decrease in the OFV.
 The structural pharmacokinetic model was used to 
examine the effects of different subject and dialysis co-
variates on the estimated pharmacokinetic model pa-
rameters and the associated IIV parameters. Subject 
weight was significantly associated with Cl s  and V c  as ev-
ident from the drop in OFV of 15 and 5 points upon ad-
dition of subject weight as a covariate on Cl s  and V c , re-
spectively. The addition of subject weight as a covariate 
on Cl s  led to a marked decrease in IIV estimate from 55.7 
to 0.3%. Similarly, addition of subject weight as a covari-
ate on V c  led to a decrease in IIV from 90.7 to 50.7%. The 
relationship between subject weight and each of Cl s  and 
V c  was explained by equations 7 and 8, respectively:
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 Table 1.  Dosing regimens used to simulate gentamicin exposure
Regi-
men
Initial
loading
dose
mg/kg
Follow-
up doses
mg/kg
Timing of follow-up doses
 A1  2  1  immediately after every other SDHD 
 A2  2  0.5  immediately after each SDHD 
 B1  3.1  2.75  1 h before every other SDHD 
 B2  3.1  1.375  1 h before each SDHD 
 C1  3  3  1 h before every other SDHD 
 C2  3  1.5  1 h before each SDHD 
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 where Cl s,TV  and V c,TV  are the population estimates of 
systemic clearance and apparent volume of distribution 
in central compartment and WT is the subject’s weight. 
The power terms describing the effects of subject weight 
on the Cl s  and V c  were estimated to be 1.97 with a relative 
standard error of 24.8% and 2.27 with a relative standard 
error of 54.6%, respectively.  Table 2 shows the final pa-
rameter estimates from the final covariate model. The 
final covariate model was able to accurately predict the 
observed gentamicin plasma concentration-time profiles 
for the 6 subjects as shown in  figure 1 . There was no sta-
tistically significant impact of single-pool Kt/V urea , equil-
ibrated Kt/V urea , and weekly standard Kt/V (as dialyzer-
specific covariates) on Cl dial  (data not shown).
 Table 2.  Gentamicin population pharmacokinetic parameter estimates for the structural and the covariate mod-
els
 Parameter  Structural model  F inal covariate model 
 population 
 estimate 
 relative 
 standard 
 error % 
 IIV  population 
 estimate 
 relative 
 standard 
 error % 
 IIV 
 Cls, ml/min 6  20.8  55.7 7.6 5.5 0.3 
 Vc, liters 9.5  38.1  90.7 12.1  23.2  50.7 
 Vp, liters 10.6 2.2  NA 10.5 5.1  NA 
 Cld, ml/min  116.2  12.3  NA  128.7 8.8  NA 
 Cldial, ml/min  139.5  15.2  34.5  134.2  15.9  29.3 
 NA  = No interindividual variability was estimated for that parameter. 
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 Fig. 1. Observed and model-predicted gentamicin plasma concentration-time profiles for the 6 subjects. Solid 
lines represent the model individual predicted concentrations and the closed circles represent the observed con-
centrations.
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 Gentamicin exposure was simulated after six dosing 
regimens.  Figure 2 shows the simulated plasma concen-
tration-time profiles (mean of 1,000 simulations) for both 
every other day and daily regimens. Postdialysis dosing 
regimens (A 1  and A 2 ) led to about 90% of simulated sub-
jects achieving C max   6 8 mg/l after the first dose but al-
most none of the subjects achieving this target after the 
second and third doses. With predialysis dosing, about 
70–80% of simulated subjects achieved a C max   6 8 mg/l 
after all doses of the every other day regimens (B 1  and C 1 ) 
and after the first dose of the daily dosing regimens (B 2  
and C 2 ;  tables 3 ,  4 ).
 The calculated 48-hour AUC values based on simula-
tions showed that, although all subjects achieved AUC 
 6 140 mg  h/l/48 after the first dose in regimens ‘A 1 ’ and 
‘A 2 ’, only 33–44 and 12% achieved it after the second and 
third doses, respectively. Predialysis every-other-day reg-
imens resulted in 37–50% of simulated subjects achieving 
an AUC  6 140 mg  h/l/48 h. Similarly, less than 50% of 
simulated subjects achieved this target after the predialy-
sis daily regimens (except for following first dose). 
 Discussion
 Estimated gentamicin systemic clearance was 7.6 ml/
min with a mean calculated elimination half-life of ap-
proximately 35 h. This estimate of half-life during inter-
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 Fig. 2. Simulated concentration-time profiles (mean of 1,000 sim-
ulations) for every-other-day ( a ) and daily ( b ) regimens. Regimen 
A 1  = Initial dose of 2 mg/kg followed by follow-up doses of 1 mg/
kg after every other SDHD session; Regimen A 2  = initial dose of 
2 mg/kg followed by follow-up doses of 0.5 mg/kg after each 
SDHD session; Regimen B 1  = initial dose of 3.1 mg/kg followed by 
follow-up doses of 2.75 mg/kg after every other SDHD session; 
Regimen B 2  = initial dose of 3.1 mg/kg followed by follow-up dos-
es of 1.375 mg/kg after each SDHD session; Regimen C 1  = initial 
dose of 3 mg/kg followed by follow-up doses of 3 mg/kg after every 
other SDHD session; Regimen C 2  = initial dose of 3 mg/kg fol-
lowed by follow-up doses of 1.5 mg/kg after each SDHD session. 
 Table 3.  AUC, peak, and trough gentamicin plasma concentrations on days 1, 3, and 5 following each of the six simulated dosing reg-
imens
 Regimen  Day 1  Day 3  D ay 5 
 AUC, mg  h/l  Cmax, mg/l  Cmin, mg/l  AUC, mg  h/l  Cmax, mg/l  Cmin, mg/l  AUC, mg  h/l  Cmax, mg/l  Cmin, mg/l 
 A1  208829  10.782.1  1.980.3  132816  6.381  1.280.2  123815  5.980.9  1.280.2 
 A2  225833  10.781.9  3.380.3  137817  4.380.6  2.380.2  123815  3.880.5  2.280.2 
 B1  132832 9.281.7  1.180.4  132835  8.981.8  1.180.5  132836  8.981.8  1.180.5 
 B2  169838 9.181.6  2.280.6  128835  5.581.2  1.980.6  125834  5.381.2  1.980.6 
 C1  128830 8.981.7  1.180.4  142837  9.781.9  1.280.5  144839  9.781.9  1.280.5 
 C2  170838 8.881.6  2.380.6  138836  5.981.4  2.180.6  135836  5.881.3  2.180.6 
 Dat a presented as means 8 SD. AUC values are for 48-hour intervals. 
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dialysis periods is similar to what was estimated previ-
ously  [8] . Similar estimates of gentamicin systemic clear-
ance during interdialytic periods have also been reported 
 [11, 12] . Dialytic clearance was estimated to be 134 ml/
min in our study. Previous studies have reported dialysis 
clearance values between 78 and 116 ml/min  [8, 11–14] . 
 Results of the simulations showed that with postdialy-
sis dosing, although 80–90% of subjects may achieve a 
C max   6 8 mg/l following the first dose, none of the simu-
lated subjects achieved that target after subsequent doses. 
On the other hand, predialysis dosing regimens per-
formed similarly and better than postdialysis regimens in 
terms of percent of simulated subjects achieving C max   6 8 
mg/l. More than 70% of simulated subjects achieved a 
C max   6 8 mg/l after all doses of every-other-day dosing 
regimens (B 1  and C 1 ). These results indicate that predi-
alysis dosing of gentamicin may perform better than 
postdialysis regimens in achieving effective concentra-
tions due to the presence of remaining gentamicin con-
centrations from the previous dose. The above results 
also show that every-other-day predialysis dosing per-
forms better than daily dosing in terms of achieving ef-
ficacy targets. This might be due to the smaller dose used 
with daily regimens and the inability to increase such 
dose due to the associated risk of toxicity. 
 In terms of the toxicity target, every-other-day regi-
mens performed generally better than daily regimens. 
Less than 20% of the subjects achieved a C min   ! 2 mg/l 
after the daily dosing regimen (A 2 ) and only 33–61% 
achieved the same target after the daily regimens (B 2  and 
C 2 ). These results indicate that daily dosing in patients on 
SDHD may lead to sustained high trough concentrations 
potentially predisposing to aminoglycoside toxicity. 
Hence, every-other-day dosing is more suitable to allow 
for adequate removal of gentamicin between doses. The 
above results also show that predialysis and postdialysis 
dosing may perform the same when it comes to achieving 
nontoxic concentrations. This is expected given the fact 
that dosing before or after the dialysis would have a great-
er effect on the peak rather than trough concentrations.
 Achievement of predetermined exposure targets was 
also assessed using 48 h interval AUC values. All six dos-
ing regimens performed similarly in terms of achieving a 
toxicity target of AUC  ^  240 mg  h/l/48 h with all subjects 
achieving this target (except for first dose of regimen A 2 ). 
Unlike the results of the peak concentrations, the predi-
alysis regimens performed worse than the postdialysis 
regimens in terms of achieving an AUC  6 140 mg  h/l/
48 h after the first dose. After subsequent doses, regimen 
‘C’ performed consistently better than regimen ‘B’ with 
almost 50% of the subjects achieving the AUC target in 
regimens ‘C 1 ’ and ‘C 2 ’ after all subsequent doses assessed. 
Although worse after the first dose, regimen ‘C’ still per-
formed better than regimen ‘A’ after subsequent doses. 
Taking these results together with the results of peak con-
centrations, we can conclude that predialysis dosing per-
forms generally better than postdialysis dosing in terms 
of achieving effective gentamicin concentrations.
 The results were compared to those obtained previ-
ously from simulations of every-other-day dosing in sub-
 Table 4.  Percent of simulated subjects achieving AUC and peak and trough concentration targets following each of the six simulated 
dosing regimens
 Regi-
 men 
 Day 1  Day 3  Day 5 
 AUC, mg  h/l  Cmax
 ≥8 mg/l 
 Cmin 
 <2 mg/l 
 AUC, mg  h/l  Cmax
 ≥8 mg/l 
 Cmin
 <2 mg/l 
 A UC, mg  h/l  Cmax
 ≥8 mg/l 
 Cmin
 <2 mg/l 
 ≤240  ≥140  140–
 240 
 ≤240  ≥140  140–
240 
 ≤2 40  ≥140  140–
240 
 A1 86.9  98.6  85.5  87.1  58.5  100  32.7  32.7 0.2  99.5  100  11.8  11.8 0  99.9 
 A2 42.3  99.7  42  89.4 0  100  43.5  43.5 0 9.3  100  11.2  11.2 0  18.9 
 B1  100  37.2  37.2  77.8  97.2 99.9  37.2  37.1  70.8  93.9 99.8  37.7  37.5  70.9  93.5 
 B2 96.4  76.5  72.9  77.9  39.1 99.7  32.1  31.8 2.1  57.8 99.8  29.1  28.9 1.3  60.5 
 C1  100  32.2  32.2  72.7  98 99.3  48.6  47.9  81.5  91.5 99.1  50.1  49.2  82.3  89.8 
 C2 96.1  75.9  72  71.8  32.8 99.1  44.1  43.2 6.9  46.5 99.5  41.7  41.2 5.2  47.5 
 Dat a presented as percent of 1,000 simulated subjects achieving AUC between 140 and 240 mg  h/l/48 h, below 240 mg  h/l/48 h, or 
above 140 mg  h/l/48 h, and percent of 1,000 simulated subjects achieving Cmax ≥8 mg/l and Cmin <2 mg/l. AUC on day 5 excludes the 
last 24 h of the week period. 
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jects undergoing thrice-weekly hemodialysis  [8] . Percent-
ages of simulated subjects achieving C max   6 8 mg/l were 
similar between the two studies for all doses. On the oth-
er hand, all three regimens performed better in our study 
in terms of achieving the toxicity target of C min   ! 2 mg/l. 
This can be due to differences in the effectiveness of the 
dialyzer used in our study or due to the more effective 
removal of gentamicin with more frequent dialysis ses-
sions. Such results indicate that regimens B 1  and C 1  may 
be as effective and less toxic when given to subjects un-
dergoing SDHD compared to subjects on thrice-weekly 
hemodialysis. The more frequent dialysis with SDHD is 
expected to enhance gentamicin removal leading to low-
er trough concentrations while achieving peak concen-
trations similar to those achieved with thrice-weekly he-
modialysis. 
 This study has some limitations. Data used to develop 
the pharmacokinetic model were obtained from a rela-
tively small sample of dialysis patients. Also, our data did 
not include pharmacodynamics measurements of drug 
efficacy or institutional minimum inhibitory concentra-
tion values. This study, hence, represents a pharmacody-
namics simulation study that predicts drug efficacy based 
on simulated exposure. This is a relatively common ap-
proach that has been used before to help guide dosing 
regimens in special patient populations.
 Conclusions
 Gentamicin is effectively removed during SDHD us-
ing the Exeltra 150 dialyzer with an estimated Cl dial  high-
er than reported in previous studies. Results of the simu-
lations indicate that predialysis every-other-day regi-
mens may be as effective and less toxic than postdialysis 
regimens and that the same every-other-day regimens 
can be used for subjects undergoing thrice-weekly or 
SDHD.
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